{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-030175","form_type":"8-K","ticker":"OCGN","cik":"0001372299","company_name":"Ocugen, Inc.","filed_at":"2023-08-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.728609+00:00","generated_at":"2026-06-11T05:30:25.406633+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"low","headline":"Ocugen reports Q2 2023 financial results; pipeline update highlights NR2E3 gene therapy","bullets":["Reported financial results for quarter ended June 30, 2023; no specific figures available in filing text.","Business update discussed gene therapy programs including NR2E3 modifier gene and NHR platform.","Presentation materials furnished as Exhibit 99.1 describe 'molecular reset' approach for retinal diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-030175","json":"https://secwatch.observer/filing/0001628280-23-030175.json","markdown":"https://secwatch.observer/filing/0001628280-23-030175.md","text":"https://secwatch.observer/filing/0001628280-23-030175.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372299/000162828023030175/0001628280-23-030175-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372299/000162828023030175/ocgn-20230822.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T05:30:25.406633+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"59ab2fe45a4299d9fdd08bdf5ff3523aa95fc301","claim":"Ocugen, Inc. reported financial results for the quarter ended June 30, 2023.","evidence_excerpt":"Ocugen, Inc. (the \"Company\") held a conference call and webcast earlier today to discuss its financial results for the quarter ended June 30, 2023, along with a general business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372299/000162828023030175/0001628280-23-030175-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}